StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) company profile

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.65−0.23 (-5.93%)

Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –

About Anbio Biotechnology

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Anbio Biotechnology is a biotechnology company that designs and supplies in vitro diagnostic (IVD) solutions, including instruments, assays, reagents, and retail self-test products. Its offerings span testing technologies such as fluorescent immunoassay (FIA), chemiluminescent immunoassay (ChLIA), molecular testing, dry chemistry, and lateral flow immunoassay (LFIA). These diagnostic solutions address respiratory conditions, COVID-19, and various non-respiratory health indications. The company sells to consumers, healthcare providers, health systems, enterprises, and governmental procurement bodies.

Anbio Biotechnology conducts operations primarily across European markets and sells its products globally, supported by CE markings and regional regulatory authorizations. The company engages third-party laboratories and manufacturers for research and production, relying on two key suppliers and a small group of key customers for a significant share of its business. The company maintains its principal executive offices in Frankfurt am Main, Germany.

Summary of the business section of Anbio Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Anbio Biotechnology
Founded
2021
Headquarters
Frankfurt Am Main, 2M
Address
Friedrich-Ebert-Anlage 49 60308
Phone
4916096247281
Employees
27, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
E9
Fiscal year ends
December 31
Auditor
GGF CPA LTD, Guangzhou PRC

Stock & identifiers

Ticker
NNNN
Exchange
Nasdaq
IPO date
Feb 19, 2025
Shares outstanding
144M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1982708
FIGI
BBG01RL0JPJ9
Share class FIGI
BBG01RL0JQX1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael LauCEO–
Chris TianCBO–
Suki SongCFO–
Michael W.C ZhangDirector–
David H. HsuDirector–
Cany XuDirector–
Nancy HartzlerDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 19, 2025
Exchange
Nasdaq
First trading day
Feb 19, 2025
First-day close
$5.77
Lock-up ends (est.)
Aug 18, 2025

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this annual report, we have 27 staff members including full time employees and contractors on an as needed basis.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?